Loading clinical trials...

A Trial for Patients With Advanced/Recurrent Endometrial Cancer | Clinical Trials | Clareo Health

COMPLETEDPHASE2

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

A Phase II Evaluation of Pemetrexed in the Treatment of Recurrent or Persistent Endometrial Carcinoma

NCT00377520•Eli Lilly and Company

Summary

The intent of this protocol is to screen a new agent for activity in patients with advanced or recurrent endometrial carcinoma. This phase II trial is studying how well pemetrexed disodium works in treating patients with advanced or recurrent endometrial carcinoma.

Eligibility

Age

All ages

Sex

FEMALE

Healthy Volunteers

Inclusion Criteria

•Patients must have recurrent or persistent endometrial adenocarcinoma, which is refractory to curative therapy or established treatments.
•Patients must have measurable disease.
•Patients must have had one prior chemotherapeutic regimen for management of endometrial carcinoma.
•Patients must have signed an approved informed consent.
•Patients of childbearing potential must have a negative serum pregnancy test prior to the study entry and be practicing an effective form of contraception during the study and for at least 3 months following the last dose of Pemetrexed.
•Patients must discontinue nonsteroidal anti-inflammatory (NSAIDs) medications 2-5 days prior to and for 1-2 days after receiving Pemetrexed, depending on the half-life of the NSAIDs treatment.
•Patients must agree to this schedule in conjunction with every dose of Pemetrexed.
•Patients must receive 350-1000 mcg of folic acid (e.g. one prenatal vitamin) starting 7 days prior to the first treatment with Pemetrexed.
•Patients must be able to ingest 350-1000 mcg of folic acid daily until 3 weeks after the last dose of Pemetrexed.
•Patients must receive 4 mg Dexamethasone by mouth twice daily, 1 day prior to the dose, the day of and the day after every dose of Pemetrexed.
+2 more criteria

Exclusion Criteria

•Patients who have had prior therapy with Pemetrexed
•Patients who have received radiation to more than 25% of marrow bearing areas

Locations (1)

Gynecologic Oncology Group 215-854-0770

Philadelphia, Pennsylvania, United States

Key Dates

Start Date

September 1, 2006

Primary Completion Date

October 1, 2007

Completion Date

September 1, 2008

Last Updated

November 20, 2009

Enrollment

ACTUAL participants

Conditions

NeoplasmsNeoplasms by SiteUrogenital NeoplasmsGenital Neoplasms, FemaleUterine NeoplasmsEndometrial NeoplasmsCancer of EndometriumEndometrial CancerCancer of the EndometriumEndometrium CancerNeoplasms, Endometrial

Interventions

pemetrexed

DRUG

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

NCT07213804

Ovarian NeoplasmsFallopian Tube Neoplasms+2 more

View study

RECRUITINGNA

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

NCT07159659

Thoracic Neoplasms

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: November 20, 2009Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Trial for Patients With Advanced/Recurrent Endometrial Cancer

Inclusion Criteria

Exclusion Criteria

A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

Post-operative Medium Chain Triglyceride Diet May Reduce Hospital Stay Following Lung Resection

A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer

Collection of Serum and Tissue Samples From Patients With Biopsy-Proved or Suspected Malignant Disease

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

ML Score Prediction of Cardiotoxicity in Cancer Patients Receiving Anthracycline Chemotherapy or HER2-Targeted Therapies